Quarterly report pursuant to Section 13 or 15(d)

Nature of Business (Details Narrative)

v3.24.2
Nature of Business (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Oct. 03, 2023
May 11, 2023
Feb. 16, 2024
May 31, 2024
May 31, 2023
Aug. 31, 2023
Common stock shares issued       15,810,205   8,091,650
Exercise price       $ 5.49    
Net loss attributable to shareholders       $ 3,600,000 $ 5,500,000  
Accumulated deficit       $ 49,400,000    
Securities Purchase Agreement [Member]            
Common stock shares issued 889,272   1,444,741      
Pre-funded warrants issued 729,058   113,702      
Common stock shares issued during period 1,618,330   1,558,443      
Offering price per share $ 0.97   $ 2.31      
Sale price per share of warrants 0.9699   2.8875      
Exercise price $ 0.0001   $ 2.185 $ 0.95    
Aggregate common stock shares issued 729,058   54,546 1,622,250    
Net proceeds from offering $ 1,250,000   $ 3,000,000      
Gross proceeds from sale of common stock 73     $ 1,541,137    
Gross proceeds from sale of common stock $ 1,569,780 $ 1,541,137 $ 2,837,664      
October 3, 2023 [Member] | Securities Purchase Agreement [Member]            
Pre-funded warrants issued 729,058          
Common stock shares issued during period 1,618,330          
Offering price per share $ 0.97          
Exercise price $ 0.0001          
Gross proceeds from sale of common stock $ 1,569,780          
Gross proceeds from sale of pre funded warrants $ 73          
February 16, 2024 [Member] | Securities Purchase Agreement [Member]            
Pre-funded warrants issued     113,702      
Common stock shares issued during period     1,298,702      
Offering price per share     $ 0.0001      
Exercise price     $ 2.185      
Gross proceeds from sale of common stock     $ 2,837,664      
Gross proceeds from sale of pre funded warrants     $ 11